285 related articles for article (PubMed ID: 32663622)
1. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
[TBL] [Abstract][Full Text] [Related]
2. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
[TBL] [Abstract][Full Text] [Related]
3. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of renal damage in plasma cell dyscrasias: an overview.
Merlini G; Pozzi C
Contrib Nephrol; 2007; 153():66-86. PubMed ID: 17075224
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
Palladini G; Milani P; Malavasi F; Merlini G
Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
Godara A; Palladini G
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
[TBL] [Abstract][Full Text] [Related]
7. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
8. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
Del Giudice ML; Galimberti S; Buda G
Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
[TBL] [Abstract][Full Text] [Related]
9. Primary systemic amyloidosis with skin and cardiac involvement: a case report.
Trajber Horvat A; Trčko K; Jurčić V; Marko PB
Acta Dermatovenerol Alp Pannonica Adriat; 2018 Mar; 27(1):45-47. PubMed ID: 29589647
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].
Gödecke V; Schmidt JJ; Bräsen JH; Koenecke C; Haller H
Internist (Berl); 2019 Jan; 60(1):10-22. PubMed ID: 30635666
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
12. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory.
Herrera GA
Ann Diagn Pathol; 2000 Jun; 4(3):174-200. PubMed ID: 10919389
[TBL] [Abstract][Full Text] [Related]
13. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Lee H; Tay J; Duggan P; McCulloch S; Neri P; Bahlis NJ; Jimenez-Zepeda VH
Eur J Haematol; 2021 Mar; 106(3):340-345. PubMed ID: 33197297
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
15. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.
Sher T; Fenton B; Akhtar A; Gertz MA
Blood; 2016 Oct; 128(15):1987-1989. PubMed ID: 27543437
[No Abstract] [Full Text] [Related]
16. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
[TBL] [Abstract][Full Text] [Related]
17. Histopathological atlas of renal diseases: light chain deposition disease.
Ferrario F; Rastaldi MP
J Nephrol; 2005; 18(5):499-502. PubMed ID: 16299674
[TBL] [Abstract][Full Text] [Related]
18. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.
Buxbaum J; Gallo G
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1235-48. PubMed ID: 10626147
[TBL] [Abstract][Full Text] [Related]
19. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Parrondo RD; Majeed U; Sher T
Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab for the treatment of AL amyloidosis.
Sidiqi MH; Gertz MA
Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
